Trials / Not Yet Recruiting
Not Yet RecruitingNCT07500298
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (estimated)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.
Detailed description
Primary Objective •To determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of SAR445877 + FOLFOX6 and bevacizumab in patients with MSS metastatic CRC. Secondary Objective •To evaluate the antitumor efficacy of SAR445877 + FOLFOX6 and bevacizumab in participants with MSS metastatic CRC.
Conditions
- Phase 1
- SAR445877
- FOlfox6
- Bevacizimab
- First Line Treatment
- Metastatic Colorectal Cancer (CRC)
- Microsatellite Stable
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAR445877 | Given by IV |
| DRUG | FOLFOX6 | Given by IV |
| DRUG | Bevacizumab | Given by IV |
Timeline
- Start date
- 2026-09-03
- Primary completion
- 2030-12-27
- Completion
- 2032-12-27
- First posted
- 2026-03-30
- Last updated
- 2026-03-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07500298. Inclusion in this directory is not an endorsement.